Cardio-rheumatology: it’s time to collaborate

[1]  I. Bruce,et al.  EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome , 2022, Annals of the Rheumatic Diseases.

[2]  Deepak L. Bhatt,et al.  Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. , 2022, The New England journal of medicine.

[3]  L. Fraenkel,et al.  Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis , 2020, BMC Rheumatology.

[4]  J. Pope,et al.  Appropriate cardiovascular disease risk assessment in systemic lupus erythematosus may be lacking in rheumatology practice. , 2018, Clinical and experimental rheumatology.

[5]  James T. Elder,et al.  Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study , 2018, The Journal of Rheumatology.

[6]  A. Ogdie,et al.  Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics , 2017, The Journal of Rheumatology.

[7]  J. Primdahl,et al.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update , 2016, Annals of the rheumatic diseases.

[8]  D. Gladman,et al.  Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? , 2013, Lupus.

[9]  I. Holme,et al.  Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic , 2012, Annals of the rheumatic diseases.

[10]  Maureen A. Smith,et al.  Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. , 2011, Arthritis and rheumatism.